Replimune Group, Inc. (REPL) Financials

REPL Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 333.6 million 123.1 million
Sept. 30, 2025 389.5 million 126.1 million
June 30, 2025 469.5 million 132.8 million
March 31, 2025 551.3 million 135.5 million

REPL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -66.1 million 7.0 million
Sept. 30, 2025 -82.6 million 8.3 million
June 30, 2025 -79.8 million 8.8 million
March 31, 2025 -54.9 million 8.3 million

REPL Net Income

No data available :(

REPL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 269.1 million 47.6 million 28.7 million
Sept. 30, 2025 323.6 million 47.2 million 29.1 million
June 30, 2025 403.3 million 46.8 million 29.5 million
March 31, 2025 483.8 million 46.4 million 29.8 million

REPL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2025 92.2 million
Sept. 30, 2025 91.9 million
June 30, 2025 91.5 million
March 31, 2025 80.6 million

REPL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 135000 53.1 million 18.7 million -
Sept. 30, 2025 1.3 million 57.9 million 26.4 million -
June 30, 2025 2.7 million 57.8 million 32.6 million -
March 31, 2025 1.1 million 54.5 million 24.5 million -

REPL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 - 1.6 million
Sept. 30, 2025 - 1.6 million
June 30, 2025 - 1.7 million
March 31, 2025 1.5 million 848000

REPL

Price: $8.88

52 week price:
1.50
13.24

Earnings Per Share: -3.44 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 354500

Market Capitalization: 782.0 million

Links: